CCIA
ACRS icon

Campbell & Co Investment Adviser’s Aclaris Therapeutics ACRS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,771
Closed -$217K – 743
2022
Q3 		$217K Buy
13,771
+294
+2% +$4.63K 0.05% 594
2022
Q2 		$188K Buy
+13,477
New +$189K 0.05% 614

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Campbell & Co Investment Adviser's ACRS Position: Q4 2022 in Review

Campbell & Co Investment Adviser sold out of Aclaris Therapeutics (ACRS) in Q4 2022, closing a stake of 13,771 shares — an estimated $217K sold.

Campbell & Co Investment Adviser first reported a position in ACRS in Q2 2022 and held it in 2 quarters. The position peaked at $217K in Q3 2022. 128 funds tracked by Wall St. Rank hold ACRS as of Q4 2022.

  • Campbell & Co Investment Adviser reported no remaining Aclaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 13,771 Aclaris Therapeutics shares in Q4 2022, an estimated $217K.
  • Campbell & Co Investment Adviser first reported a position in Aclaris Therapeutics in Q2 2022 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Aclaris Therapeutics position peaked at $217K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.